Expertise in
13
conditions

Dr. Stephen B. Heitner

Cardiology
Heart RHYTHM Consultants P.C.
9427 SW Barnes Rd Ste 495, 
Portland, OR 
21 Years of Experience
Expertise in
13
conditions
Heart RHYTHM Consultants P.C.
9427 SW Barnes Rd Ste 495, 
Portland, OR 

Overview

Stephen Heitner is a Cardiologist practicing medicine in Portland, Oregon. He has been practicing medicine for over 21 years.

Dr. Heitner is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Transthyretin Amyloidosis, Pacemaker Implantation, and Heart Bypass Surgery.

He is actively involved in clinical research, co-authoring 124 peer reviewed articles and participating in 10 clinical trials.

Specialties

Cardiology

Licenses

Internal Medicine in OR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Heart RHYTHM Consultants P.C.
9427 SW Barnes Rd Ste 495, Portland, OR 97225

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
Enrollment Status: Completed
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drug: JK07
Study Phase: Phase 1
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Mavacamten
Study Phase: Phase 2
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS
Enrollment Status: Completed
Publish Date: September 05, 2023
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Withdrawn
Publish Date: May 31, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Enrollment Status: Terminated
Publish Date: August 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

124 Total Publications

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Journal: Circulation
Published: August 29, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral required
Before you request

University Andrology Lab LLC

3303 S Bond Ave, 
Portland,, OR 
 (4.8 miles away)
503-494-1775
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Firas Zahr is a Cardiologist practicing medicine in Portland,, Oregon. Dr. Zahr is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Mitral Valve Regurgitation, Tricuspid Regurgitation, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Zahr is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required
Before you request

University Andrology Lab LLC

3303 S Bond Ave, 
Portland,, OR 
 (4.8 miles away)
503-494-1775
Languages Spoken:
English, French, Italian, Spanish
See accepted insurances
Accepting New Patients

Craig Broberg is a Cardiologist practicing medicine in Portland,, Oregon. Dr. Broberg is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Congenital Heart Disease (CHD), Tetralogy of Fallot, Transposition of the Great Arteries, Heart Transplant, and Heart Valve Repair. Dr. Broberg is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request

University Andrology Lab LLC

3303 S Bond Ave, 
Portland,, OR 
 (4.8 miles away)
503-494-1775
Languages Spoken:
English, Czech, Slovak
See accepted insurances
Accepting New Patients
Offers Telehealth

Maros Ferencik is a Cardiologist practicing medicine in Portland,, Oregon. Dr. Ferencik is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Coronary Heart Disease, Acute Coronary Syndrome, Unstable Angina, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Ferencik is currently accepting new patients.

Frequently Asked Questions about Dr. Stephen B. Heitner

How do I make an appointment with Dr. Stephen B. Heitner?

You can book an appointment with Dr. Stephen B. Heitner by calling their office at 503-216-1661. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen B. Heitner a top-rated expert for Hypertrophic Cardiomyopathy (HCM)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen B. Heitner is classified as an Elite expert for Hypertrophic Cardiomyopathy (HCM), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen B. Heitner specialize in?

While Dr. Stephen B. Heitner is a Cardiology, they have specific expertise in Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, and Transthyretin Amyloidosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Cardiology.

Does Dr. Stephen B. Heitner participate in research or clinical trials?

Yes. Dr. Stephen B. Heitner has published 124 articles and abstracts on conditions like Hypertrophic Cardiomyopathy (HCM). You can view a list of Dr. Stephen B. Heitner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heitner's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile